<table>
<thead>
<tr>
<th>Title</th>
<th>A dual colour dual fusion fluorescence in situ hybridisation study on the genesis of complex variant translocations in chronic myelogenous leukaemia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author(s)</td>
<td>So, CC; Wan, TSK; Yip, SF; Chan, LC</td>
</tr>
<tr>
<td>Citation</td>
<td>Oncology Reports, 2008, v. 19 n. 5, p. 1181-1184</td>
</tr>
<tr>
<td>Issued Date</td>
<td>2008</td>
</tr>
<tr>
<td>URL</td>
<td><a href="http://hdl.handle.net/10722/88783">http://hdl.handle.net/10722/88783</a></td>
</tr>
<tr>
<td>Rights</td>
<td>This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.</td>
</tr>
</tbody>
</table>
A dual colour dual fusion fluorescence in situ hybridisation study on the genesis of complex variant translocations in chronic myelogenous leukaemia

CHI-CHIU SO, THOMAS SHEK-KONG WAN, SZE-FAI YIP and LI-CHONG CHAN

Department of Pathology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, P.R. China

Received August 31, 2007; Accepted October 22, 2007

Abstract. Complex variant 9;22 translocations occur in a significant minority of chronic myelogenous leukaemia (CML) patients. Different mechanisms of their formation have been described. We report dual colour dual fusion fluorescence in situ hybridisation data in 12 Chinese CML patients with complex translocations. Three previously reported breakpoint hotspots in a third partner chromosome (14q32, 17q25, 1q21) were observed. In 10/12 (83.3%) patients, the abnormality occurred as a single step 3-break event. Only a single abnormal clone harbouring the complex translocation was seen in this group. The remaining 2 cases in the chronic phase showed a 4-break mechanism (2/12, 16.7%). Deletion of 5' ABL at der(9) was not observed in any of the 12 patients, however, the loss of 3' BCR was observed in 1 patient (1/12, 8.3%). Together with previous findings, these data suggest that these variant translocations occur more often as a 3-break single-step process with no reciprocal ABL-BCR fusion. On the other hand, a 4-break event is also regularly seen during the initial stages of leukaemogenesis, which likely predisposes to der(9) deletion. The observed difference in rates of der(9) deletion reported in a series of CML patients with variant translocations may be related to a difference in rates of a 4-break event.

Introduction

Complex variant translocation of (9;22) has an incidence of ~10% in patients with chronic myelogenous leukaemia (CML) (1,2). The most common is a 3-way balanced t(9;22;v). Previous studies using a chromosome 22 painting probe indicated either a one-step (3) or two-step process (4) in the genesis of these variants. Recent studies using the fluorescence in situ hybridisation (FISH) method showed the occurrence of either mechanism in different and occasionally the same cases (5,6).

Chronic myelogenous leukaemia with der(9) deletion has been shown to carry a poor prognosis (7-10). Complex variant translocations in CML have been reported in many studies to be associated with a significantly higher incidence of der(9) deletion than CML with classical Ph translocation (weighted average 40.4 vs 12.7%) (reviewed in ref. 6). These translocations impart a poor survival to this group of patients when compared to CML patients with classical t(9;22) or variant translocations without der(9) deletion (5).

In this study, we employed D-FISH to investigate the mechanism of formation of the most common 3-way t(9;22;v) in 12 Chinese patients with CML. The incidence of der(9) deletion was also determined in this cohort of patients.

Materials and methods

Clinical samples. A search for complex variant translocation in CML patients was performed in our cytogenetics database. Twelve cases were identified which had available materials for D-FISH analysis - 10 in the chronic phase and 2 in the accelerated phase. All showed a balanced 3-way t(9;22;v).

Conventional cytogenetic analysis. Cytogenetic analysis was performed on Giemsa banded (G banded) metaphases obtained through short-term synchronised and unsynchronised cultures of bone marrow cells based on standardised protocols. Karyotypes were reported in accordance with ISCN 1995.

D-FISH. Detection of BCR-ABL and ABL-BCR gene fusions was performed using BCR/ABL dual colour dual fusion translocation probes (Abbott Molecular/Vysis, Des Plaines, IL), according to the manufacturer's instructions. In total, 300 interphase nuclei on cytopsin smears were analysed for the presence of fusion signals. In selected cases, metaphase FISH was performed on G banded metaphases relocated using microscope coordinates, as described previously (11). A 2G2O1F pattern indicated a one-step 3-break event whereas a 1G1O2F pattern indicated a two-step 4-break event.

Results

Table I shows the disease status during the investigation and full karyotype of the 12 cases with balanced 3-way
translocations. Ten patients were in the chronic phase and 2 in the accelerated phase. No patient was in the blast phase. None of them had received tyrosine kinase inhibitor therapy prior to investigation. Residual normal metaphases were detected in only 1 case by conventional cytogenetics. Recurrent breakpoints in a third partner chromosome were observed at 5q11.2 (n=2) and 10p14 (n=2). Clonal evolution was evident in 2 cases. Case 9 showed a subclone with additional trisomy 8 at disease acceleration. Case 12 harboured a stem line with classical t(9;22), which was not seen in any other case in this series.

In 10 cases, D-FISH revealed (8 chronic and 2 in the accelerated phase) a 2G2O1F pattern indicating a one-step 3-break event. A reciprocal ABL-BCR fusion signal was absent. Normal cells with a 2G2O pattern were observed in 3 of these 10 cases in significant proportions (8-22%) of interphase nuclei examined. In the remaining 2 cases of the chronic phase CML, a 1G1O2F pattern was seen indicating a two-step 4-break mechanism. This included the only case (Case 12) showing a stemline with classical t(9;22) and another case (Case 11) with a single abnormal clone of variant translocation. Metaphase FISH analysis of these 2 cases showed the presence of a fusion signal on der(9), indicating an intact ABL-BCR fusion gene and a further break distal to the ABL breakpoint in the 3-way translocation (Fig. 1a, b and c). None of the 12 cases showed a loss of the 5' ABL signal on der(9), however, the loss of the 3' BCR signal on der(9) was observed in a subclone in 1 case (Case 11). The rate of der(9) deletion was thus 1/12 (8.3%).

Discussion

In CML, the most common form of complex variant translocations is 3-way balanced t(9;22;v). Indirect evidence suggests a one-step process in the formation of these variant translocations in most incidences: i) They are usually observed at initial diagnosis of the chronic phase, although are not normally detected as new cytogenetic abnormalities during disease evolution. ii) By themselves they do not signify disease acceleration. iii) These variants are most often found in the absence of a clone bearing classical t(9;22).

The availability of D-FISH provides a useful tool in investigating the mechanism of the formation of these variant translocations in CML. Using this technique, a 3-break process (2G2O1F) and a 4-break two-step process (1G1O2F) have both been observed. The expected predominance of a 3-break process was confirmed, which accounted for ~50% of the cases in recent large series (5,6). However, a significant minority of cases with a 4-break two-step process was regularly seen (1,5,6). The incidence ranged from 6 to 21.4%. The same observation was also evident in the present study (2/12, 16.7%). As expected, a 4-break process was detected in cases showing a classical t(9;22) stemline (as Case 12 in the present study). Notably, it was also found in patients with a single abnormal clone showing variant translocation (as Case 11 in the present study). This suggests that a 4-break mechanism can also operate at the initial stages of leukaemogenesis, either as a one-step 4-break process or with a second translocation between der(9)t(9;22) and a third partner chromosome occurring shortly after t(9;22) in the same leukaemic stem cell. These 2 scenarios are expected to be rare compared to a simpler 3-break process. Therefore, the resulting 4-break D-FISH pattern was less commonly observed in most series. We recently reported a similar case of the unusual 4-break process in a patient with acute promyelocytic leukaemia and a single abnormal clone of 47.XY,+8.t(15;17)(q22;q12;q22) (12).

A major difficulty is seen when D-FISH is employed to study how variant translocations arise in CML. It is not
applicable to cases with der(9) deletion as one cannot deduce whether a 3-break or 4-break process has occurred before the deletion. This has been an important confounding factor as der(9) deletion was observed in an average of 40% of cases in most reported series (6). In the largest series reported to date, Reid et al. (5) detected a frequency of 3-break and 4-break process in 52 and 11% of 54 patients with variant translocation, respectively. However, a significant 37% of the patients showed a der(9) deletion by D-FISH and thus a translocation mechanism could not be assigned. As proposed by Huntly et al. (9), each recombination at der(9q34) should have a finite probability leading to deletion around the region. It is therefore reasonable to postulate that many, if not the majority, of those cases with der(9) deletion had a 4-break translocation. This would be in agreement with the finding that in series with a low frequency of der(9) deletion (1) including the present one, a much higher rate of 3-break events was seen (83 to 94%). The suggestion that a 4-break mechanism can also operate at the initial stages of leukaemogenesis and thus predisposes to deletion, as discussed above, is also consistent with the many evidences favouring a 9q deletion event occurring at the time of formation of the Ph translocation (13).

The reason for the possible difference in rates of a 4-break event among different series that might have explained the observed variation in frequency of der(9) deletion is not apparent. An ethnic genetic difference cannot be excluded. A similar low rate of der(9) deletion (13.7%) was also reported in a cohort of Chinese CML patients with variant translocations (14). However, the rate of a 4-break event was not shown.

Three reported breakpoint hotspots in a third partner chromosome (14q32, 17q25, 1q21) (2) were observed in our cases. In addition, 2 cases each with breakpoint at 5q31 and 10p13 were found, which have not been found previously as breakpoint hotspots. These breakpoint hotspots are located preferentially in the GC-richest regions of the genome. GC-rich regions have high densities of genes and repetitive Alu sequences. They also coincide with open chromatin with high transcription activities. These elements may increase the chance of chromosome breakage and repair or the juxtapositioning of Alu-rich sites, resulting in chromosomal recombination and translocation (2).

In conclusion, complex variant translocation in CML occurs more often as a 3-break single-step process with no reciprocal ABL-BCR fusion. On the other hand, a 4-break event is also regularly observed during the initial stages of leukaemogenesis. Although by itself it may not have a
prognostic implication, a 4-break process likely predisposes to der(9) deletion which is a strong predictor of survival. The observed low frequency of der(9) deletion among Chinese CML patients with variant translocations can be due to a low rate of a 4-break event. Further studies confirming and explaining this difference are warranted in order to have a better understanding of the pathogenesis of CML.

References